Fig. 6: Antibody and pseudoneutralization responses to third vaccine dose.
a, Antibody responses to the third vaccine dose according to therapy; concurrent or anti-CD20 therapy within 6 months in B-NHL (anti-CD20), concurrent BTK inhibitors or venetoclax in B-NHL (BTKi/VEN) and concurrent chemotherapy in HL (chemo), compared to those not on treatment (I B-NHL and A B-NHL and HL); two-sided Wilcoxon test, ****P < 0.0001. b, IFN-γ T-cell responses in healthy donors and participants with lymphoma who had a negative result (initial NR) or positive result (initial R) after two vaccine doses; two-sided Wilcoxon test, *P = 0.0361, **P = 0.0122. c, Good agreement is observed between binding of participant IgG to the wild-type SARS-CoV-2 and Omicron, Delta, Alpha, Beta and Gamma variants, undertaken in pre-D3 and post-D3 samples. The antibody concentration for each variant (value on inside of the y axis) equivalent to anti-S wild-type IgG 400 BAU ml−1 is shown; two-sided Spearman correlation and simple linear regression.
